Test screens for opioid substitution drugs as well as benzodiazepines and opiates
Fingerprint sample collection in seconds, with results in 10 minutes.
Intelligent Fingerprinting, the pioneering company behind the world’s first portable fingerprint-based drug testing system, has launched a new drug screening test designed to meet the needs of drug rehabilitation organisations looking for a simpler, more dignified and non-invasive approach to supporting their clients’ progress towards recovery.
The test is fingerprint-based, taking less than a minute to collect a client’s fingerprint sweat samples onto the small Drug Screening Cartridge and just ten minutes to screen for the opioid substitution drugs methadone and buprenorphine, which are commonly used to assist recovery from substance abuse. The new drug treatment screening Cartridge also tests for benzodiazepines as well as opiates, significantly enhancing the range of Intelligent Fingerprinting products available to drug treatment service providers.
The simple, dignified and non-invasive nature of fingerprint-based drug testing makes it ideally suited to the needs of drug treatment services. The portable system is designed for use in a variety of situations, including non-clinical settings, making it easier for drug treatment programme staff to set up screening sessions, collect samples, administer tests and obtain results quickly. This allows test outcomes to be discussed with clients during the same session – a key factor in helping to keep a client’s drug recovery on track – while also giving drug treatment staff the opportunity to build closer relationships with the clients who most need their support.
Intelligent Fingerprinting’s drug treatment test is also more dignified, hygienic, and convenient than traditional testing methods that require saliva or urine samples. In addition to the new test, drug treatment organisations will continue to benefit from the award-winning organisation’s other drug testing products which include a four-panel test for methamphetamine, cocaine, opiates and cannabis, as well as a laboratory confirmation service.
“With the development of our new drug test we’re responding directly to feedback from drug treatment providers requesting a combined screen for methadone and buprenorphine, which are often prescribed as part of a recovery programmeme,” commented Intelligent Fingerprinting’s Dr Paul Yates. “Customer reaction to fingerprint-based drug screening has proved very positive from drug recovery organisations that are already using our system.
“With our enhanced product range we’re now able to support the drug rehab sector’s key drug screening requirements, confirming Intelligent Fingerprinting’s non-invasive, dignified and rapid drug screening solution as particularly applicable for drug programmeme operators looking for an open and transparent way to support and track their clients’ progress towards recovery,” he added.
Fingerprint-Based Drug Testing
Intelligent Fingerprinting’s drug testing solution features a small, tamper-evident Drug Screening Cartridge which takes less than a minute to collect fingerprint sweat samples. The Intelligent Fingerprinting portable analysis unit then reads the Cartridge and displays a positive or negative result on-screen for all drugs in the test within 10 minutes.
About Intelligent Fingerprinting:
Intelligent Fingerprinting’s portable Drug Screening System works by analysing fingerprint sweat. It is non-invasive, fast and cost-effective, with sample collection taking seconds and simultaneous screening for multiple drug groups in ten minutes. A laboratory confirmation service is also available.
The system has applications within many sectors and customers include employers in safety-critical industries such as construction, transport and logistics firms, drug treatment and family safeguarding organisations, as well as UK coroners. The company has distributors across the globe, including the USA.
Founded in 2007, Intelligent Fingerprinting is a spin-out company from the University of East Anglia (UEA). The company is based in Cambridge, England and employs around 30 people.
